1. Home
  2. ACAD vs SLM Comparison

ACAD vs SLM Comparison

Compare ACAD & SLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$22.23

Market Cap

3.8B

Sector

Health Care

ML Signal

N/A

Logo SLM Corporation

SLM

SLM Corporation

N/A

Current Price

$22.95

Market Cap

4.5B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
SLM
Founded
1993
1972
Country
United States
United States
Employees
N/A
1788
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.5B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ACAD
SLM
Price
$22.23
$22.95
Analyst Decision
Buy
Buy
Analyst Count
22
11
Target Price
$30.55
$31.09
AVG Volume (30 Days)
1.3M
3.8M
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
2.26%
EPS Growth
69.12
N/A
EPS
2.30
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
$3.35
Revenue Next Year
$11.70
$5.68
P/E Ratio
$9.64
$6.91
Revenue Growth
40.45
N/A
52 Week Low
$14.45
$17.77
52 Week High
$28.35
$34.55

Technical Indicators

Market Signals
Indicator
ACAD
SLM
Relative Strength Index (RSI) 51.18 54.92
Support Level $21.51 $20.82
Resistance Level $22.97 $22.86
Average True Range (ATR) 0.57 0.95
MACD 0.07 0.05
Stochastic Oscillator 68.03 51.51

Price Performance

Historical Comparison
ACAD
SLM

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About SLM SLM Corporation

SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

Share on Social Networks: